Is Dexamethasone The Next HCQ For Indian Pharma?
Zydus Cadila, Wockhardt, Cadila, Cipla Could Gain
While the jury is still out on dexamethasone being the new hero in the fight against COVID-19 after the hype around hydroxychloroquine has died down, Indian pharma is watching developments closely. Gains of companies like Zydus Cadila, Wockhardt, Cadila and Cipla in the domestic market will be constrained by price caps while any increase in exports will depend on emergency use authorizations
You may also be interested in...
More news from across the sector, including Novartis's non-profit pledge on medicines and Zydus Cadila commencing Phase I vaccine trial.
Coronavirus Update: Regeneron Races Into Phase III Trial Of Antibodies To Block Coronavirus Infection
Regeneron and NIAID kick off a Phase III prevention trial for antibody cocktail REGN-COV2.
Join us for a quick audio roundup of five useful things to know from Scrip’s recent coverage of the global biopharmaceutical industry.